RPS16 and gastric cancer: The survival rate after 100 months for GC patients with overexpression of ATP5A1, ATP5B, ATP5D, COX6C, COX7A2, MT-ATP8, ND4, ND6, NDUFS3, RPL8, and RPS16 genes showed < 20%, 40%, > 20%, 40%, > 20%, < 40%, 30%, > 30%, > 20%, > 20%, and > 20%, respectively [71].